AIXPLORE
LIVE

Serial Number

79426071

Owner

ProteoGenix

Attorney

Richard A. Castellano

Filing Date

Jan 23, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AIXPLORE Trademark

Serial Number: 79426071 • Registration: 8190939

AIXPLORE is a trademark filed by ProteoGenix on January 23, 2025. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ProteoGenix (3 trademarks)

19 Rue de la Haye

Entity Type: 92

Trademark Details

Filing Date

January 23, 2025

Registration Date

March 31, 2026

Published for Opposition

February 10, 2026

Goods & Services

Downloadable or recorded computer software for conducting research in the fields of drug discovery, diagnostics, genetics, proteomics and identification, drug research, research and design of antibodies, proteins, peptides, biological products and chemicals, pharmaceutical research; downloadable or recorded computer software for use in antibody discovery and identification; downloadable or recorded artificial intelligence software for facilitating drug discovery, affinity maturation, engineering of biological products, studies of molecular interactions, humanization and identification, drug research, antibody research and design, pharmaceutical research; downloadable or recorded machine learning software for use in drug discovery and identification, drug research, antibody research and design, pharmaceutical research; downloadable software for conducting research and diagnostics in the field of genomics, proteomics, omics and developing biological products; downloadable or recorded big data generation software

Software as a service (SAAS) services featuring software for use in conducting research in the fields of drug discovery, diagnostics, genetics, proteomics and identification, drug research, antibody, protein, peptide, biological product and chemical product research and design, pharmaceutical research; medical research services in the field of medicine discovery; biological research; scientific analysis and research in the field of drug discovery, affinity maturation, biological product engineering, studies of molecular interactions, humanization and identification, drug research, antibody, protein, peptide, biological and chemical research and design, pharmaceutical research; antibody sequencing technology research; research and development services related to AI in the field of drug discovery and identification, drug research, antibody research and design, pharmaceutical research; research and development in the field of drug discovery and identification, drug research, research and design of antibodies, proteins, peptides, biological products and chemicals; research and development services in the field of antibody technology; electronic data storage and providing on-line non-downloadable software using artificial intelligence (AI) for machine learning

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 31, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 15, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 24, 2025 TROA
REFUSAL PROCESSED BY IB
Sep 5, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 17, 2025 RFCS
REFUSAL PROCESSED BY MPU
Aug 17, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 9, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jul 8, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 3, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 22, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 22, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 19, 2025 REPR